Everolimus-d4

Cat. No.: IBDI-437366

Everolimus-d4 is the deuterium labeled Everolimus. Everolimus (RAD001) is a Rapamycin derivative and a potent, selective and orally active mTOR1 inhibitor. Everolimus binds to FKBP-12 to generate an immunosuppressive complex. Everolimus inhibits tumor cells proliferation and induces cell apoptosis and autophagy. Everolimus has potent immunosuppressive and anticancer activities.

Product Details

Target	mTOR | FKBP | Autophagy | Apoptosis
Molecular Weight	962.25
Synonyms	RAD001-d4, SDZ-RAD-d4
SMILES	O=C1N2[[email protected]](CCCC2)([H])C(O[[email protected]](CC([[email protected]@H](/C=C([[email protected]]([[email protected]](C([[email protected]@H](C[[email protected]@H](/C=C/C=C/C=C([[email protected]](C[[email protected]@]3([H])O[[email protected]@](C1=O)([[email protected]@H](CC3)C)O)OC)\C)C)C)=O)OC)O)\C)C)=O)([H])[[email protected]](C)C[[email protected]]4C[[email protected]]([[email protected]@H](CC4)OC([2H])([2H])C([2H])([2H])O)OC)=O

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.